74904-29-3

Basic information

• Product Name: 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one
• Synonyms: 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one;8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one
• CAS NO: 74904-29-3
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.19984
• Mol File: 74904-29-3.mol
• Article Data: 15

Chemical Properties

• Melting Point: 148-149 °C(Solv: benzene (71-43-2))
• Boiling Point: 439.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.159±0.06 g/cm3(Predicted)
• PKA: 14.77±0.20(Predicted)
• CAS DataBase Reference: 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one(74904-29-3)
• EPA Substance Registry System: 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one(74904-29-3)

Safety Data

• Hazardous Substances Data: 74904-29-3(Hazardous Substances Data)

Usage

General Description

3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one, also known as sabcomeline, is a chemical compound with the molecular formula C11H11NO2. It belongs to the class of isoquinolinones and is a potent and selective antagonist for the muscarinic acetylcholine receptor subtype M1. 3,4-dihydro-8-Methoxyisoquinolin-1(2H)-one has been studied for its potential therapeutic effects in the treatment of schizophrenia, Alzheimer's disease, and other cognitive disorders. It is also being investigated for its potential as a treatment for drug addiction and other neurological disorders. Sabcomeline has shown promising results in preclinical studies, demonstrating its potential as a novel pharmacological agent for various neurological and psychiatric conditions.

Upstream product

• 15184-99-3 N,N-dimethyl-3-methoxybenzylamine 
• 81625-31-2 2-(ethoxycarbonyl)-3-methoxyphenylacetonitrile 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 108-95-2 phenol 
• 6968-35-0 7-hydroxy-indan-1-one 
• 24552-27-0 3-chloropropionic acid phenyl ester 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 5411-61-0 4-bromo-7-methoxy-2,3-dihydro-1H-inden-1-one 
• 66192-02-7 3-(2-bromo-5-methoxyphenyl)propanoic acid 
• 81625-30-1 2-(ethoxycarbonyl)-3-methoxybenzyl chloride 
• 81625-29-8 N,N-dimethyl-2-(ethoxycarbonyl)-3-methoxybenzylamine 
• 163713-49-3 3-(3-Methoxy-phenyl)-propionyl azide 
• 40478-49-7 3-(3-methoxyphenyl)propanoyl chloride 

Downstream Products

• 81625-33-4 N-(benzenesulfonyl)-3,4-dihydro-3-methoxyisocarbostyril 
• 73903-30-7 8-Methoxy-2-methyl-1,2,3,4-tetrahydroisochinolin 
• 81625-22-1 1-<4-(benzyloxy)benzyl>-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-20-9 1-(3,4-dimethoxybenzyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-41-4 1-<4-(benzyloxy)benzyl>-2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-40-3 1-<4-(benzyloxy)benzyl>-2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-37-8 2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-39-0 2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-35-6 1-hydroxy-2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-36-7 2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 1723-70-2 8-methoxyisoquinoline 
• 32999-37-4 1,2,3,4-tetrahydroisoquinoline-8-ol 
• 464900-21-8 8-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 34146-68-4 8-methoxy-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.